Re: When are they going to learn?
Alright, I was asked what do I proposed to do? Here is what I did. I sold out my PTLA position(took a significant loss) and brought ESPR at high $50s. I wanted to use this example to illustrate what is the right path forward for a small biotech company to operate. ESPR has a potential product that is worth $2.5 global sale(same as PTLS's Andexxa) that is waiting for the FDA to approve this month. The European CHMP has already signaled a positive outcome. The ESPR senior management(who also have their MBAs) already signed a European commercial agreement with Daiichi Sankyo Europe in January 2019 for upfront and potential milestone payment for up to $1.2 billion. The CEO has publicly said that they wanted to focus on the U.S. market, but if someone offers them a substantial offer then anything can happen. Now, we all know this is the right path for a small biotech company to take. So how is this different than what's happening at PTLA? I wanted to use this example to show that the senior management and the BOD at PTLA is the worst period. They disgraced their academic MBA training(not looking after the best interest of the shareholders) period.